Business ❯ Pharmaceuticals

Mergers and Acquisitions

Pfizer Legal Disputes Investment Corporate Strategy Antitrust Issues Sanofi Biontech Takeover Bids Bidding Wars Corporate Transactions BioNTech Healthcare Acquisition Transactions Valuation Weight-loss Drugs Novartis Weight Loss Federal Trade Commission Company Strategy Obesity Treatments Corporate Competition Novo Nordisk vs Pfizer Market Strategy Antitrust Law Market Competition Acquisition Strategies Novo Nordisk BioMarin Competitive Strategy Biotechnology Investment Funds Foreign Investment Company Acquisitions Tender Offer AstraZeneca Bristol Myers Squibb Pharma Industry

Merck Reportedly Weighs $28–$32 Billion Deal for Revolution Medicines After AbbVie Denial

No agreement has been announced, with Revolution declining to comment on the renewed takeover speculation.

Stories older than 24h

Amgen Buys Oxford Spinout Dark Blue Therapeutics for Up to $840 Million

BioMarin to Acquire Amicus for $4.8 Billion in Cash

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

Pfizer Sues Metsera and Novo Nordisk to Block Termination of $4.9 Billion Deal

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Pfizer Strikes U.S. Drug-Pricing Pact, Wins Exemption From 100% Import Tariff

Pfizer to Buy Metsera in Up to $7.3 Billion Obesity Bet

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy